Hayashi T, et al. - In this prospective multicenter study, researchers evaluated both risk factors and a candidate treatment strategy for delayed chemotherapy-induced nausea and vomiting (CINV) in patients with solid cancers undergoing low-emetic-riskIn this prospective multicenter study, researchers evaluated both risk factors and a candidate treatment strategy for delayed chemotherapy-induced nausea and vomiting (CINV) in patients with solid cancers undergoing low-emetic-risk chemotherapy (LEC). This investigation was conducted in 13 hospitals and included 222 patients with solid cancers undergoing LEC. According to the recommended guideline, the current use of antiemetic prophylaxis seems to effectively control delayed CINV in patients undergoing LEC. They suggested that patients with a history of CINV, Eastern Cooperative Oncology Group performance status score ≥1, acute CINV, and single-day antiemetic prophylaxis should be carefully observed, and their treatment should be adjusted according to their symptoms. For those patients who develop acute CINV, the use of multiple-day dexamethasone might be beneficial, particularly when it is accompanied by anorexia.